Congenital Aniridia Patient Questionnaire

Congenital Aniridia Clinical Trial

— Aniridia-Quizz  

Official title:

Congenital Aniridia Patient Questionnaire

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05390801
• Other study ID #: APHP220119
• Secondary ID: 2021-A02363-38
• Status: Recruiting
• Start date: June 8, 2023
• Est. completion date: June 8, 2025

Study information

• Verified date: June 2023
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: Alejandra Daruich, MD, PhD
• Phone: 1 44 38 19 69
• Email: alejandra.daruich-matet[@]aphp.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Congenital aniridia is a pan-ocular genetic disease characterized by a partial or complete absence of the iris, hence its name. The prevalence ranges from 1 / 40,000 to 1 / 96,000 births, but it may be underestimated. This condition combines several types of eye damage and could associate systemic manifestations, with a variable phenotype and genotype. This study aims to identify eye and systemic manifestations in congenital aniridia and to determine the patients' knowledge of their own disease through a survey prepared by ophthalmologists from the Ophthalmology Department of Necker-Enfants Malades Hospital, reference center in France for this pathology. The patient fills it out only once.

Description:

Congenital aniridia is a pan-ocular genetic characterized by partial or complete absence of the iris, hence its name. The prevalence ranges from 1 / 40,000 to 1 / 96,000 births, but it may be underestimated. This condition combines several types of eye damage : - Partial or complete absence of iris, iris abnormalities - Glaucoma - Cataract - Corneal opacifications with neovascularization - Foveal hypoplasia with nystagmus - Hypoplasia of the optic nerve The signs of the disease vary from one individual to another, even within the same family. Iris abnormalities and foveolar hypoplasia are the most constant signs. Affected patients have a highly compromised visual prognosis in adulthood, and are very often considered visually impaired with criteria for legal blindness. Congenital aniridia can also be associated with several severe systemic manifestations, including syndromic aniridia (WAGR syndrome and Gillespie syndrome). The major gene responsible for autosomal dominant forms of congenital aniridia is PAIRED BOX GENE 6 (PAX6) (MIM#607108) with over 500 pathogenic variants reported to date. Congenital aniridia is therefore a rare, pan-ocular disease associating systemic manifestations, with a variable phenotype and genotype. This study aims to identify eye and systemic manifestations in congenital aniridia and to determine the patients' knowledge of their own disease through a survey prepared by ophthalmologists from the Ophthalmology Department of Necker-Enfants Malades Hospital, reference center in France for this pathology. The patient fills it out only once.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: June 8, 2025
• Est. primary completion date: June 8, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Any patient = 18 years old with congenital aniridia and able to respond independently to the study survey,
• or patients under 18 years old with congenital aniridia, whose parents can answer the study survey,
• adult patients or holders of parental authority and minor patients informed and not opposed to participation in the study.

Exclusion Criteria:

• Patients with neurological disorders preventing them from answering the survey, except in the case of minor patients, if the parents can answer for the patient.

Related Conditions & MeSH terms

• Aniridia
• Congenital Aniridia

Intervention

Other:
• Survey
Survey developed by ophthalmologists from the Ophthalmology Department of the Necker-Enfants Malades Hospital, fill out only once by patients with congenital aniridia in order to identify eye and systemic manifestations in congenital aniridia and to determine the patients' knowledge of their own disease.

Locations

Country	Name	City	State
France	Hôpital Necker-Enfants Malades	Paris

Sponsors (1)

Lead Sponsor	Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Ocular and systemic manifestations in congenital aniridia	To identify eye and systemic manifestations in congenital aniridia through a survey prepared by ophthalmologists. The answers of the survey will be compared with data from the patient's medical file.	24 months
Secondary	Patient's autonomy	Descriptive analysis of the patient's answers and data from the patient's medical file to determine the impact of the disease on patient's autonomy.; Questions in the survey concerning patient's autonomy will be compared to the data collected in the medical file. For instance: help with activities of daily living, computer/phone use, lifestyle, outdoor and indoor travel, etc.	24 months
Secondary	Patients knowledge	Descriptive analysis of the patient's answers and data from the patient's medical file to determine how well patients know their disease and potential complications.; Questions in the survey concerning the etiology, complications and evolution of the disease will be compared with the data collected in the medical file in order to determine the degree of knowledge of the patients of the disease.	24 months
Secondary	Factors influencing patient knowledge	To determine the influence of factors such as age, sex, origin and profession on patients' knowledge of their disease according to survey answers.	24 months
Secondary	Parental knowledge	Descriptive analysis of the parents' answers and data from the patient's medical file to determine parents' knowledge of their child's disease and potential complications.; For patients < 18 years old, the parents' answers of the questions in the survey concerning the etiology, complications and evolution of the disease will be compared with the data collected in the medical file.	24 months